CRSP — Crispr Therapeutics AG Cashflow Statement
0.000.00%
Last trade - 00:00
- $5.75bn
- $4.05bn
- $371.21m
- 46
- 21
- 95
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 66.9 | -349 | 378 | -650 | -154 |
Depreciation | |||||
Non-Cash Items | 33.5 | 67.9 | 116 | 110 | 67 |
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -48.4 | 33.4 | 26.9 | 19.8 | -194 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 56.7 | -238 | 539 | -496 | -260 |
Capital Expenditures | -6.68 | -18.4 | -81.7 | -37.2 | -12 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 8.01 | -523 | -954 | -221 | 387 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 1.32 | -541 | -1,035 | -259 | 375 |
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 431 | 1,016 | 251 | 38.6 | 62.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 489 | 237 | -246 | -716 | 177 |